The number of liver cancer cases in Africa will double by 2050 unless steps are taken to provide treatment for HBV

Biomarkers of hepatocellular carcinoma

Patients with liver cancer are diagnosed at a very late stage in Africa. We have found that the median survival is less than 90 days in our cohort (manuscript under preparation). The PROLIFICA team is working on the identification of biomarkers which might be used for early diagnosis of cirrhosis or HCC (Ladep et al Hepatology 2014). Additional studies are currently on progress. This work is led by Prof. Simon Taylor-Robinson, Prof. Elaine Holmes and Dr Maimuna Mendy.